Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties
Chemical Biology & Drug Design · 2026-02 · 107 (2)
DOI: 10.1111/cbdd.70235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 17.02.2026. Verfasst von Solange A Tanyi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon. Hauptthemen laut MEDLINE: HIV-1, Histone Deacetylase Inhibitors, Virus Latency, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation, LifeArc.
Abstract (Originalsprache)
The goal of this project is to design, synthesize, and test compounds that combine fragments derived from natural products (NPs) for their HIV‐1 latency‐reversal properties, particularly those that act by histone deacetylase inhibition. A fragment library was created by implementing the Retrosynthetic Combinatorial Analysis Procedure (RECAP) on a collection of NPs isolated from different regions in Africa. The top‐scoring docked fragments within the histone deacetylase (HDAC1) binding site were reconstructed to design and synthesize chemical scaffolds that have not been previously described as HDAC inhibitors. Synthesized compounds were then tested for the ability to reverse HIV latency in J‐Lat 10.6 cells and/or inhibit cellular histone deacetylases. The synthesized scaffolds include indole‐chalcones and aminobenzamides. Of fifty‐one synthesized compounds, compound S2‐13 was the most active with HIV latency reversal 20.2% ± 6.2% of J‐Lat 10.6 cells at 10 μg/mL (25.1 μM), which was comparable to the HIV latency‐reversing agent Prostratin. S2‐13 also inhibited HDAC activity with a half‐maximal inhibitory concentration (IC 50 ) of 17.0 μM. We demonstrate that the use of pseudo‐NPs can identify novel chemical scaffolds that can reverse HIV latency and inhibit HDACs in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon.
- Department of Chemistry, Faculty of Science, University of Buea, Buea, Cameroon.
- Department of Chemistry, Higher Teachers' Training College, University of Buea, Buea, Cameroon.
- Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- The Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
ORCID-Profile: Solange A Tanyi, Donatus B Eni, Mohamed Abdelsalam, Mathieu J M Tjegbe, Matthias Schmidt, Roland N Ndip, Ian Tietjen, Wolfgang Sippl, Fidele Ntie-Kang
Förderung
- Gates Foundation
- Bill and Melinda Gates Foundation
- LifeArc
- Alexander von Humboldt-Stiftung
Zitieren
APA
Tanyi, S. A., Eni, D. B., Abdelsalam, M., Tjegbe, M. J. M., Schmidt, M., Ndip, R. N., Tietjen, I., Sippl, W., & Ntie-Kang, F. (2026). Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties. Chemical Biology & Drug Design, 107(2). https://doi.org/10.1111/cbdd.70235
Vancouver
Tanyi SA, Eni DB, Abdelsalam M, Tjegbe MJM, Schmidt M, Ndip RN, et al. Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties. Chemical Biology & Drug Design. 2026;107(2). doi:10.1111/cbdd.70235
BibTeX
@article{Tanyi2026,
author = {Tanyi, Solange A and Eni, Donatus B and Abdelsalam, Mohamed and Tjegbe, Mathieu J M and Schmidt, Matthias and Ndip, Roland N and Tietjen, Ian and Sippl, Wolfgang and Ntie-Kang, Fidele},
title = {Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {2},
doi = {10.1111/cbdd.70235}
}
EUVIMED